Epub 2010 Jun 16
Xenobiotica 1993
Most patients begin to notice improvements within 46 weeks, with more significant benefits seen over 36 months

The blots were incubated with the following primary antibodies: GAPDH (1:10,000, Proteintech, 60,0041-Ig), HK2 (1:1000, Abcam, ab209847), TH (1:5000, Abcam, ab137869), LDHA (1:1000, Cell Signaling Technology, 3582S), Bax (1:1000, Abcam, ab32503), Bcl2 (1:1000, Abcam, ab32124), AMPK1/2 (H 300) (1:500, Santa Cruz Biotechnology, sc-25,792), phospho-AMPK1/2 (Thr 183/172) (1:500, Santa Cruz Biotechnology, sc-101,630), phospho-Akt (Thr308) (1:1000, Cell Signaling Technology, 4056S), Akt (1:1000, Cell Signaling Technology, 9272S), phospho-mTOR (Ser2448) (1:1,000, Cell Signaling Technology, 5336S), mTOR (7C10) (1:1000, Cell Signaling Technology, 2983S), -Synuclein (1:1000, Cell Signaling Technology, 4179S), BDNF (1:1000, Abcam, ab108319), PGC-1 (1:100, Abcam, ab191838), PDK1 (1:2000, Abcam, ab202468), PKM2 (1:1000, Cell Signaling Technology, 4053), GPX4 (1:1000, Abcam, ab125066), UCP2 (1:1000, Abcam, 89326), ATP5A (1:1000, Cell Signaling Technology, 18023), UQCRC2 (1:1000, Cell Signaling Technology, 99258), MTCO1 (1:1000, Abcam, ab14705), SIRT1 (1:1000, Abcam, ab110304), HIF-1 (1:1000, Abcam, ab308433), NRF1 (1:1000, Abcam, ab175932), and NRF2 (1:1000, Abcam, ab207223)

This product provides 250 mg of reduced glutathione per capsule